21 September 2020
Medicine Compliance Aid Stability
GilenyaNovartis Pharmaceuticals UK Ltd
Novartis Pharmaceuticals UK Ltd
Capsules 500 micrograms
A3 · Amber 3 No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from moisture
Store in airtight container and protect from moisture.
18 September 2015
Lactation Safety Information
Low levels anticipated in milk due to the drug's properties
No published evidence of safety
Serious adverse effects reported in adults
22 September 2020